Le Lézard
Classified in: Health
Subjects: PDT, TDS, FDA

OsteoRemedies® Announces the First FDA Cleared Dual-Antibiotic Spacer and Bone Cement with Gentamicin and Vancomycin


MEMPHIS, Tenn., Nov. 1, 2018 /PRNewswire/ -- OsteoRemedies®, LLC, a company focused on providing simple solutions to complex disorders, is pleased to announce the launch of the REMEDY SPECTRUMtm? GV Hip Spacer System and SPECTRUMtm? GV Bone Cement.  Building on its portfolio consisting of the only pre-made modular spacer system with Gentamicin for Hip, Knee and Shoulders, the REMEDY SPECTRUMtm? GV Hip System will provide surgeons with the first ever broad-spectrum treatment option with both Gentamicin and Vancomycin.

"We are very proud to have the first FDA cleared dual-antibiotic spacer system and bone cement offering," stated Chris Hughes, President and Chief Executive Officer of OsteoRemedies®.  "Since we started the company in 2013, our commitment to the growing problem of treating joint infections has been our mission.  The amount of science, testing and clinical data supporting this launch is unparalleled in our space.  The addition of the SPECTRUMtm? GV portfolio, further enhances our vision for providing simple solutions for complex disorders for revision infection remedies and achieving a market leadership position in our niche."

The launch of the SPECTRUMtm? GV system will begin November 1- 4 at the American Academy of Hip and Knee Surgeons (AAHKS) in Dallas, Texas where OsteoRemedies® will be exhibiting at Booth # 308.  In addition to the introduction of SPECTRUMtm, OsteoRemedies® will also be showcasing the newly launched REMEDY® Acetabular Cup Spacer, which in conjunction with the REMEDY® Hip System, provides the only Pre-formed all PMMA hip spacer option on the market. The existing portfolio will also be displayed, including the REMEDY® Modular Hip, Knee and Shoulder Spacer, OSTEOBOOST®? RBK and FLORASEAL®? Microbial Sealant along with UNITE® Antibiotic Bone Cement.

About OsteoRemedies®, LLC
OsteoRemedies provides simple solutions to complex musculoskeletal disorders.  Their first introduction was the REMEDY® Spacer System. This was the first available modular system for hip, knee and shoulder two-stage infection revision arthroplasty.  The REMEDY® Spacer System and REMEDY SPECTRUMtm? GV Hip Spacers are indicated for temporary use (maximum 180 days) as an adjunct to total joint replacement in skeletally mature patients undergoing a two-stage procedure due to a septic process and where gentamicin or gentamicin and vancomycin are the most appropriate antibiotics based on the susceptibility pattern of the infecting micro-organisms.  SPECTRUMtm GV Bone Cement is indicated for use with the REMEDY SPECTRUMtm GV Hip Spacer System.  Other product offerings include OSTEOBOOST®? RBK and FLORASEAL®? Microbial Sealant and UNITE®? AB Bone Cement.

The Company's web site for news releases and other information is http://www.osteoremedies.com.

Contact 
Eric Stookey
[email protected]

 

SOURCE OsteoRemedies


These press releases may also interest you

at 02:54
HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature...

at 02:50
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany?Universitätsklinikum Tübingen...

at 02:24
Today, 23 April 2024, the subscription period in SciBase Holding AB (publ) ('SciBase' or the 'Company') rights issue of units of up to approximately SEK 15 million commences (the 'Rights Issue'). The Rights Issue was resolved by the Board of...

at 02:05
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A...

at 02:00
Red Arrow Therapeutics Inc. closed a $4.5M Seed Extension round, raising from four, top-tier institutional investors in Japan. Participants of this round are: Beyond Next Ventures Inc.The University of Tokyo Edge Capital Partners Co., Ltd.Keio...

at 01:05
Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care...



News published on and distributed by: